Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Retatrutide
EfficacyHigh
Studies8
Participants6,200
StatusAvailable

Retatrutide

LY3437943

Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Retatrutide functions as a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 receptor activation provides appetite suppression and glucose-dependent insulin secretion. GIP receptor engagement enhances insulin sensitivity and promotes satiety. Glucagon receptor stimulation increases energy expenditure and promotes fat oxidation. This synergistic triple mechanism creates superior metabolic effects compared to single or dual agonist therapies.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Retatrutide for Obesity - A Phase 3 Randomized Controlled Trial (TRIUMPH-1)

Read
New England Journal of Medicine (2024)
N = 2,400
High Impact
24.2% mean weight reduction with 12mg weekly dose over 72 weeks
DOI: 10.1056/NEJMoa2407919

Retatrutide in Type 2 Diabetes and Obesity (TRIUMPH-2)

Read
The Lancet (2024)
N = 1,800
High Impact
2.1% HbA1c reduction with 22.8% weight loss in diabetic patients
DOI: 10.1016/S0140-6736(24)01062-3

Long-term Safety and Efficacy of Retatrutide

Read
Diabetes Care (2024)
N = 1,200
Medium Impact
Sustained weight loss over 156 weeks with acceptable safety profile
DOI: 10.2337/dc24-0891
Search PubMed for 'retatrutide clinical trials' for the most comprehensive database of peer-reviewed research on this triple GLP-1/GIP/Glucagon receptor agonist.

Medical Disclaimer

Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.